Edition:
United States

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

16.15USD
26 May 2017
Change (% chg)

$-0.90 (-5.28%)
Prev Close
$17.05
Open
$17.00
Day's High
$17.20
Day's Low
$16.00
Volume
124,700
Avg. Vol
157,714
52-wk High
$36.46
52-wk Low
$16.00

ALDR.OQ

Chart for ALDR.OQ

About

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated... (more)

Overall

Beta: --
Market Cap(Mil.): $814.13
Shares Outstanding(Mil.): 50.41
Dividend: --
Yield (%): --

Financials

  ALDR.OQ Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -4.45 -- --
ROI: -69.06 -8.48 -5.42
ROE: -69.17 -11.31 -4.68

BRIEF-Alder Biopharmaceuticals says presentation of positive data from Phase 2B clinical trial evaluating Eptinezumab for prevention of migraine

* Eptinezumab emerging clinical profile suggests migraine preventative benefit achieved as soon as 24-48 hours after single infusion

Apr 28 2017

BRIEF-Alder Biopharmaceuticals reports Q1 loss per share $2.00

* Alder Biopharmaceuticals announces first quarter 2017 financial and operating results

Apr 27 2017

BRIEF-Alder Biopharmaceuticals top-line results from promise 1 expected later this quarter

* Alder Biopharmaceuticals Inc - top-line results from promise 1 expected later this quarter Source text for Eikon: Further company coverage:

Apr 24 2017

BRIEF-Alder Biopharmaceuticals reports Q4 loss per share $0.97

* Alder Biopharmaceuticals announces fourth quarter and full year 2016 financial and operating results

Feb 23 2017

More From Around the Web

Earnings vs. Estimates